• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Stephen P. Mulligan, Christopher M. Ward, David Whalley, Sarah N. Hilmer Tags: Editorial Comment Source Type: research

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research